anaemia of chronic kidney disease
Haematology · 2009–2017
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| epoetin lambda Treatment of anaemia associated with intrinsic renal disease. The submission sought to allow subcutaneous administration in addition to the previously… | Jul 2017 | Recommended | none received |
| epoetin lambda Treatment of anaemia requiring transfusion (haemoglobin level less than 100 g per L) where intrinsic renal disease is the primary cause. | Jul 2010 | Recommended with restriction | no section in document |
| epoetin lambda Treatment of anaemia requiring transfusion (haemoglobin level less than 100 g per L) where intrinsic renal disease, assessed by a nephrologist, is the primary… | Jul 2010 | Recommended with restriction | no section in document |
| methoxy polyethylene glycol-epoetin beta Treatment of anaemia requiring transfusion (haemoglobin < 100 g/L) where intrinsic renal disease is the primary cause, in the context of chronic kidney disease. | Nov 2009 | Recommended with restriction | no section in document |
What the PBS pays
$58M in government benefit over 2024–25, across 61,477 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| methoxy polyethylene glycol-epoetin beta | $50.4M |
| epoetin lambda | $7.5M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| epoetin betaNEORECORMON epoetin beta (rch) 10 000 IU/0.6 mL injection syringe | 2006 | 6 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.